uniQure Announces 2019 Financial Results and Highlights Recent Company Progress ~ Patient Dosing Nearly Completed in Phase III HOPE-B Trial of E tranacogene Dezaparvovec in Hemophilia B ~ ~ First Patient Procedure in Pha

uniQure Announces 2019 Financial Results

and Highlights Recent Company Progress

Patient Dosing Nearly Completed in Phase III HOPE-B Trial of Etranacogene Dezaparvovec

~ First Patient Procedure

in Phase I/II Clinical Trial of AMT-130 in Huntington's Disease

Expected to Occur Around the End of the First Quarter of

~ Strong Balance Sheet Expected to Fund

Operations into 2022 ~

MA and Amsterdam, the Netherlands, March 2, 2020 - uniQure N.V. (NASDAQ:

QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported

its financial results for 2019 and highlighted recent progress across its business.

past year was marked by strong execution in our pivotal, Phase III HOPE-B study of etranacogene dezaparvovec in

hemophilia B for which we achieved full enrollment and expect to announce top-line data before the end of this year," stated

Matt Kapusta, chief executive officer of uniQure. "We believe etranacogene

dezaparvovec has a potential best-in-class profile as a one-time treatment for patients with hemophilia

B, and our primary goal is to advance this program for regulatory review and potential approval."

"We have also successfully screened

patients in the randomized Phase I/II clinical trial of AMT-130 in Huntington's disease and expect the first procedure to

occur around the end of this first quarter of 2020," he added. "In addition, we have continued to advance our research

pipeline of innovative AAV gene therapy candidates and further build on our proprietary, commercial-scale manufacturing capabilities.

We expect this year to be a transformational one for uniQure in which we announce new clinical data and advance our internally

discovered investigational gene therapies."

Recent Company Progress

Upcoming Investor Events

Financial Highlights

Cash Position: As of December 31,

2019, the Company held cash and cash equivalents of $377.8 million, compared to $234.9 million as of December 31, 2018. The

Company currently expects cash and cash equivalents will be sufficient to fund operations into 2022.

Revenues: Revenue for the year ended

December 31, 2019 was $7.3 million, compared to $11.3 million for the year ended December 31, 2018. The decrease in 2019 reflects

the termination of the S100A1 program for the treatment of congestive heart failure under our collaboration with Bristol-Myers

Expenses: Research and development expenses were $94.7 million for the year ended December 31, 2019, compared to $74.8 million

for the year ended December 31, 2018. The change was primarily related to increased activities associated with our ongoing clinical

studies of etranacogene dezaparvovec, the recently initiated

Phase I/II study of AMT-130, increased share-based compensation and the hiring of additional clinical and operations staff at our

SG&A Expenses: Selling, general

and administrative expenses were $33.5 million for the year ended December 31, 2019, compared to $25.3 million for the year ended

December 31, 2018. The change was primarily related to increases in personnel and consulting expenses, professional fees and share-based

compensation expenses.

Other income, net: Other expense

was $0.1 million for 2019, compared to other income of $0.6 million for 2018.

Net Loss: The net loss for the full

years 2019 and 2018 was $124.2 million, or $3.11 per share and $83.3 million, or $2.34 per share, respectively.

uniQure is delivering on the promise of

gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology

platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, hemophilia A,

Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases. www.uniQure.com

uniQure Forward-Looking Statements

press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking

statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate,"

"expect," "goal," "intend," "look forward to", "may," "plan," "potential,"

"predict," "project," "should," "will," "would" and similar expressions. Forward-looking

statements are based on management's beliefs and assumptions and on information available to management only as of the date of

this press release. These forward-looking statements include, but are not limited to, the ability to provide top-line data or any

further clinical updates and data with respect to our pivotal Phase III study of AMT-061 before the end of 2020 or ever, the ability

to submit a BLA for marketing authorization of etranacogene dezaparvovec in 2021, or ever, the risk of cessation, delay or lack

of success of any ongoing or planned clinical studies, the ability to dose the first sentinel patient in the AMT-130 Phase

I/II clinical study by around the end of the first quarter of 2020, or ever, the ability to fund

operations into 2022, whether AMT-061 proves to have a best-in-class profile as a one-time treatment for patients with hemophilia,

whether 2020 will be a transformational year for uniQure in which new clinical data is announced or investigational gene therapies

are advanced, whether we can provide a safety update for AMT-130 this year, whether the Data Safety Monitoring Board for AMT-130

will convene later in 2021, whether important imaging and biomarker data from the AMT-130 trial will be obtained in 2021, or ever,

whether IND-enabling studies for Spinocerebellar Ataxia Type 3 (SCA3) are initiated in 2020, and whether an IND application for

SCA3 will be filed in 2021, or ever. Our actual results could differ materially from those anticipated in these forward-looking

statements for many reasons, including, without limitation, risks associated with our clinical development activities, clinical

results, collaboration arrangements, regulatory oversight, product commercialization and intellectual property claims, as well

as the risks, uncertainties and other factors described under the heading "Risk Factors" in uniQure's Annual

Report on Form 10-K filed on March 2, 2020. Given these risks, uncertainties and other factors, you should not place undue reliance

on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information

becomes available in the future.

UNAUDITED CONSOLIDATED BALANCE SHEETS

UNAUDITED CONSOLIDATED STATEMENTS OF